Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 2/20 | 0.58 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.58 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.58 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.58 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.49 |
| ▸ | GJB2 | P29033 | 2/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18542463 | 1.00 | SSTR5 (0.58) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL8336531 | 1.00 | SSTR5 (0.58) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL13005449 | 1.00 | SSTR5 (0.58) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL4587088 | 1.00 | SSTR5 (0.58) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL8992036 | 1.00 | SSTR5 (0.58) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL12729388 | 1.00 | SSTR5 (0.58) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL13088352 | 1.00 | SSTR5 (0.58) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL13005380 | 1.00 | SSTR5 (0.58) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL3151671 | 0.96 | SSTR5 (0.57) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL22927969 | 0.94 | SSTR1 (0.62) | SSTR5SSTR1SSTR2SSTR4SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020232194-A1 | METHODS FOR GLYCOSYLATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2018035416-A1 | REAGENTS AND METHODS FOR GLYCOSYLATION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | ENDOTIS PHARMA (FR) | 2010-04-01 | — | — | US | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| US-6043341-A | PHOSPHONYLATING AGENTS FOR REGIOSELECTIVE AND REPRODUCIBLE CONVERSION OF PEPTIDES TO PHOSPHONIC ACID PRODRUGS | ELI LILLY & CO. (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0906915-A1 | Preparation of cyclic peptide antifungal agents | ELI LILLY AND COMPANY (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0532668-A1 | NOVEL -g(a)-GLUCOSIDASE INHIBITORS. | MERRELL DOW PHARMA (US) | 1993-03-24 | — | — | EP | disclosed |
| US-5157116-A | Antidiabetic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-10-20 | — | — | US | disclosed |
| US-5097023-A | α-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-03-17 | — | — | US | disclosed |
| WO-1991018915-A1 | NOVEL α-GLUCOSIDASE INHIBITORS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-12-12 | — | — | WO | disclosed |
| EP-0422975-A1 | Alpha-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-04-17 | — | — | EP | disclosed |
| EP-0422307-A1 | Novel alpha-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-04-17 | — | — | EP | disclosed |
| EP-0389723-A1 | Novel alpha-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-10-03 | — | — | EP | disclosed |
| EP-0390674-A1 | Novel alpha-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-10-03 | — | — | EP | disclosed |
| EP-0345104-A2 | Novel Alpha-glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-12-06 | — | — | EP | disclosed |
| EP-0344383-A1 | Novel alpha-Glucosidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | SERPINC1, F2, FUT5 | SSTR5 1014/4885SSTR1 1801/4885SSTR2 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.